Discovery/CollaGenex to develop novel treatments

[Guest guest]

Discovery/CollaGenex to develop novel treatments for respiratory

 diseases

Discovery Laboratories and CollaGenex Pharmaceuticals have formed a research

collaboration to evaluate the combination of their platform technologies for

the

development of novel respiratory disease therapeutics. The companies will

collaborate on the preclinical evaluation of an aerosolised formulation of

Discovery's humanised lung surfactants combined with CollaGenex'

IMPACS (Inhibitors of Multiple Proteases and CytokineS) compounds for the

treatment of respiratory diseases.

The objective of the collaboration will be to develop and assess formulations

of humanised lung surfactant and protease inhibitors as potential treatments

for

diseases such as chronic obstructive pulmonary disease, cystic fibrosis,

chronic

interstitial lung disease and acute lung injury.

Becki

YOUR FAVORITE LilGooberGirl

YOUNGLUNG EMAIL SUPPORT LIST

www.topica.com/lists/younglung

Pediatric Interstitial Lung Disease Society

http://groups.yahoo.com/group/InterstitialLung_Kids/